Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.

Wu YS, Shui L, Shen D, Chen X.

Oncotarget. 2017 Feb 7;8(6):10703-10713. doi: 10.18632/oncotarget.12926. Review.

3.

What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Ji T, Guo W, Yang R, Tang X, Wang Y, Huang L.

Clin Orthop Relat Res. 2017 Mar;475(3):620-630. doi: 10.1007/s11999-016-4773-8.

PMID:
26975382
4.

Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry.

Xiao WJ, Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP, Ye DW.

Oncotarget. 2015 Dec 29;6(42):44955-62. doi: 10.18632/oncotarget.5831.

5.

Conditional Survival of Esophageal Cancer: An Analysis from the SEER Registry (1988-2011).

Kim E, Koroukian S, Thomas CR Jr.

J Thorac Oncol. 2015 Oct;10(10):1490-7. doi: 10.1097/JTO.0000000000000649.

6.
7.

Long-term mortality among women with epithelial ovarian cancer.

Dinkelspiel HE, Champer M, Hou J, Tergas A, Burke WM, Huang Y, Neugut AI, Ananth CV, Hershman DL, Wright JD.

Gynecol Oncol. 2015 Aug;138(2):421-8. doi: 10.1016/j.ygyno.2015.06.005. Epub 2015 Jun 5.

8.

Identification of epithelial ovarian tumor-specific aptamers.

Benedetto G, Hamp TJ, Wesselman PJ, Richardson C.

Nucleic Acid Ther. 2015 Jun;25(3):162-72. doi: 10.1089/nat.2014.0522. Epub 2015 Apr 20.

9.

Estimating the change in life expectancy after a diagnosis of cancer among the Australian population.

Baade PD, Youlden DR, Andersson TM, Youl PH, Kimlin MG, Aitken JF, Biggar RJ.

BMJ Open. 2015 Apr 13;5(4):e006740. doi: 10.1136/bmjopen-2014-006740.

10.

Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: a multi-institutional analysis of 502 patients.

Bischof DA, Kim Y, Dodson R, Jimenez MC, Behman R, Cocieru A, Fisher SB, Groeschl RT, Squires MH 3rd, Maithel SK, Blazer DG 3rd, Kooby DA, Gamblin TC, Bauer TW, Quereshy FA, Karanicolas PJ, Law CH, Pawlik TM.

JAMA Surg. 2015 Apr;150(4):299-306. doi: 10.1001/jamasurg.2014.2881.

11.

Prognosis and conditional disease-free survival among patients with ovarian cancer.

Kurta ML, Edwards RP, Moysich KB, McDonough K, Bertolet M, Weissfeld JL, Catov JM, Modugno F, Bunker CH, Ness RB, Diergaarde B.

J Clin Oncol. 2014 Dec 20;32(36):4102-12. doi: 10.1200/JCO.2014.55.1713. Epub 2014 Nov 17.

12.

Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma.

Duchman KR, Lynch CF, Buckwalter JA, Miller BJ.

Clin Orthop Relat Res. 2014 Aug;472(8):2516-25. doi: 10.1007/s11999-014-3600-3. Epub 2014 Apr 5.

13.
14.

Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma.

Miller BJ, Lynch CF, Buckwalter JA.

Clin Orthop Relat Res. 2013 Nov;471(11):3398-404. doi: 10.1007/s11999-013-3147-8. Epub 2013 Jul 3.

15.

An individualized conditional survival calculator for patients with rectal cancer.

Bowles TL, Hu CY, You NY, Skibber JM, Rodriguez-Bigas MA, Chang GJ.

Dis Colon Rectum. 2013 May;56(5):551-9. doi: 10.1097/DCR.0b013e31827bd287.

16.

Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer.

Dikken JL, Baser RE, Gonen M, Kattan MW, Shah MA, Verheij M, van de Velde CJ, Brennan MF, Coit DG.

Ann Surg Oncol. 2013 May;20(5):1623-30. doi: 10.1245/s10434-012-2723-6. Epub 2012 Nov 10.

17.

New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research.

Sherman ME, Guido R, Wentzensen N, Yang HP, Mai PL, Greene MH.

Gynecol Oncol. 2012 Dec;127(3):645-50. doi: 10.1016/j.ygyno.2012.08.023. Epub 2012 Aug 29. No abstract available.

18.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK.

Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8.

19.

Genomic aberrations relate early and advanced stage ovarian cancer.

Zaal A, Peyrot WJ, Berns PM, van der Burg ME, Veerbeek JH, Trimbos JB, Cadron I, van Diest PJ, van Wieringen WN, Krijgsman O, Meijer GA, Piek JM, Timmers PJ, Vergote I, Verheijen RH, Ylstra B, Zweemer RP; EORTC GCG Translational Research Group.

Cell Oncol (Dordr). 2012 Jun;35(3):181-8. doi: 10.1007/s13402-012-0077-5. Epub 2012 May 12.

20.

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.

Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM.

Cancer. 2012 May 15;118(10):2674-81. doi: 10.1002/cncr.26553. Epub 2011 Sep 20.

Supplemental Content

Support Center